Literature DB >> 2983523

Mechanism of vasodilation by molsidomine.

W R Kukovetz, S Holzmann.   

Abstract

Molsidomine is enzymatically metabolized in the liver to SIN-1 and readily converted into the active metabolite SIN-1A, which carries a free nitroso group. Evidence obtained in isolated circular strips from bovine coronary arteries indicates that SIN-1 increases cyclic guanosine monophosphate in close association with its relaxant effects in coronary strips under various pharmacologic conditions, suggesting that cyclic guanosine monophosphate mediates relaxation. Various nitrovasodilators act by the same mechanism, which is stimulation of guanylate cyclase. In this study the effect of nitroglycerin depended on the presence of a special thiol, cysteine, whereas SIN-1 was active also in the absence of cysteine. Cysteine deficiency was found to be associated with tolerance. After prolonged exposure to the drug, tolerance toward nitroglycerin developed in coronary strips that was antagonized by cysteine. SIN-1 produced no significant tolerance and was also fully active in nitroglycerin-tolerant strips. We conclude that SIN-1 relaxes vascular smooth muscle by direct stimulation of guanylate cyclase, whereas nitroglycerin probably must be converted into a cyclase stimulator by a cysteine-dependent reaction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983523     DOI: 10.1016/0002-8703(85)90669-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

1.  Haemodynamic evaluation of two regimens of molsidomine in patients with chronic congestive heart failure.

Authors:  G Lehmann; G Reiniger; A Beyerle; H Zeitler; W Rudolph
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

2.  Aging differentially affects direct and indirect actions of endothelin-1 in perfused mesenteric arteries of the rat.

Authors:  Y Dohi; T F Lüscher
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

3.  Comparison of haemodynamic effects of nifedipine and molsidomine in patients with coronary artery disease.

Authors:  M Kyriakidis; G Vyssoulis; P Sfikakis; C Kyriakidis; C Pitsavos; K Valsamis; V Nomikos; P Toutouzas
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  The effects of the nitric oxide donors molsidomine and SIN-I on human polymorphonuclear leucocyte function in vitro and ex vivo.

Authors:  H Darius; L Grodzinska; J Meyer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  The nitric oxide donor molsidomine prevents ischemia/reperfusion injury of the adult rat small intestine.

Authors:  Hayrettin Oztürk; Mustafa Aldemir; Ali Ihsan Dokucu; Yusuf Yağmur; Nihal Kilinç; Ahmet Hikmet Sahin
Journal:  Pediatr Surg Int       Date:  2003-06-03       Impact factor: 1.827

6.  Inhibition of proliferation, but not of Ca2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells.

Authors:  J W Assender; K M Southgate; M B Hallett; A C Newby
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

7.  Additional molsidomine in refractory unstable angina pectoris.

Authors:  O Bertel; G Noll
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

8.  Effect of nitrate tolerance and dipyridamole on the response to SIN1 in the human isolated saphenous vein.

Authors:  M Bohyn; G Berkenboom; J Fontaine
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

9.  Influence of chronic treatment with a nitric oxide donor on fatty streak development and reactivity of the rabbit aorta.

Authors:  H Bult; G R De Meyer; A G Herman
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

10.  Mechanisms of nitrate-induced vasodilatation and tolerance.

Authors:  W R Kukovetz; S Holzmann
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.